OncoSec Medical announced today that it has entered into entered into a Warrant Exercise Agreement with certain holders of outstanding warrants to purchase up to an aggregate of 5,509,642 shares of the Company’s common stock, at its stated exercise price of $1.69 per share.
|
[13-November-2017] |
SAN DIEGO, Nov. 13, 2017 /PRNewswire/ -- OncoSec Medical (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that it has entered into entered into a Warrant Exercise Agreement with certain holders of outstanding warrants to purchase up to an aggregate of 5,509,642 shares of the Company’s common stock, at its stated exercise price of $1.69 per share. Although each holder agreed to exercise, from time-to-time and in accordance with the terms of the warrants, the holders exercised all of the warrants held by it for cash today. As a result, the Company received gross proceeds of approximately $9.3 million from the exercise of the warrants. The Company expects to use the proceeds for working capital and general corporate purposes, including primarily for its PISCES/KEYNOTE-695 clinical trial and for other clinical and research and development activities. About OncoSec Medical Incorporated OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse®, for the treatment of cancer. ImmunoPulse is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12 (tavokinogene telseplasmid [pIL-12] or “tavo”). In Phase 1 and 2 clinical trials, ImmunoPulse® IL-12 has demonstrated a favorable safety profile, evidence of anti-tumor activity in the treatment of various solid tumors, and the potential to reach beyond the site of local treatment to initiate a systemic immune response. OncoSec’s lead program, ImmunoPulse IL-12, is currently in clinical development for metastatic melanoma and triple-negative breast cancer. The program’s current focus is on the significant unmet medical need in patients with melanoma who are refractory or have relapsed on anti-PD-1 therapies. In addition to tavo, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse platform. For more information, please visit www.oncosec.com. Cautionary Note Regarding Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as “can,” “may,” “will,” “suggest,” “look forward to,” “potential,” “understand,” and similar references to future periods. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on management’s current preliminary expectations and are subject to risks and uncertainties, which may cause OncoSec’s results to differ materially and adversely from the statements contained herein. Potential risks and uncertainties that could cause actual results to differ from those predicted include, among others, the following: risks associated with market conditions; the satisfaction of customary closing conditions related to the offering; uncertainties inherent in pre-clinical studies and clinical trials, such as the ability to enroll patients in clinical trials and the risk of adverse events; unexpected new data, safety and technical issues; OncoSec’s ability to raise additional funding necessary to fund continued operations; and the other factors discussed in OncoSec’s filings with the SEC. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events. CONTACT: Media Relations
View original content with multimedia:http://www.prnewswire.com/news-releases/oncosec-receives-93-million-warrant-exercise-300555059.html SOURCE OncoSec Medical Incorporated | ||
Company Codes: NASDAQ-SMALL:ONCS |